K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone).
| Inventor | Institute |
|---|---|
| Timothy Ward | Cancer Research UK Manchester Institute |
| SKU: | 153252 |
|---|---|
| Product description: | The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation. |
| Conditional: | No |
| Production details: | The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone). |
| Cellosaurus ID: | CVCL_2967 |
| Parental cell line: | K562 |
| Disease: | Cancer |
| Cat. #: | 153252 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Blood cancer |
| Research Fields: | Cancer;Drug development |
| Organism: | Human |
| Tissue: | Lymphatic Tissue |
| Model: | Tumour line |
| Growth properties: | Suspension |
| Cancer Types In Detail: | Human caucasian chronic myelogenous leukemia (drug resistant) |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37?°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage. |
| References: |
Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550. Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.